First, newer DM medications, including Glucagon-like peptide-1 (GLP-1) agonists and Sodium-glucose cotransporter-2 inhibitors (SGLT2i), were not included in our comparison, as they were not widely available during the study period, which ended in 2017. This evidence concerns the gene GLP1R and diabetes mellitus.